How to use biomarkers of infection or ...
Document type :
Article dans une revue scientifique
Permalink :
Title :
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Author(s) :
Póvoa, Pedro [Auteur]
Universidade Nova de Lisboa = NOVA University Lisbon [NOVA]
Odense University Hospital [OUH]
Coelho, Luís [Auteur]
NOVA Medical School - Faculdade de Ciências Médicas [NMS]
Dal-Pizzol, Felipe [Auteur]
University of Southern Santa Catarina [Florianopolis] [UNISUL]
Ferrer, Ricard [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Vall d'Hebron University Hospital [Barcelona]
Huttner, Angela [Auteur]
Geneva University Hospitals and Geneva University
Conway Morris, Andrew [Auteur]
University of Cambridge [UK] [CAM]
Nobre, Vandack [Auteur]
Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] [UFMG]
Ramirez, Paula [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Rouze, Anahita [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Salluh, Jorge [Auteur]
Universidade Federal do Estado do Rio de Janeiro [UNIRIO]
D'Or Institute for Research and Education [Rio de Janeiro]
Singer, Mervyn [Auteur]
University College of London [London] [UCL]
Sweeney, Daniel A. [Auteur]
University of California [San Diego] [UC San Diego]
Torres, Antoni [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Universitat de Barcelona [UB]
Waterer, Grant [Auteur]
Royal Perth Hospital
Kalil, Andre C. [Auteur]
University of Nebraska Medical Center
Universidade Nova de Lisboa = NOVA University Lisbon [NOVA]
Odense University Hospital [OUH]
Coelho, Luís [Auteur]
NOVA Medical School - Faculdade de Ciências Médicas [NMS]
Dal-Pizzol, Felipe [Auteur]
University of Southern Santa Catarina [Florianopolis] [UNISUL]
Ferrer, Ricard [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Vall d'Hebron University Hospital [Barcelona]
Huttner, Angela [Auteur]
Geneva University Hospitals and Geneva University
Conway Morris, Andrew [Auteur]
University of Cambridge [UK] [CAM]
Nobre, Vandack [Auteur]
Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] [UFMG]
Ramirez, Paula [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Rouze, Anahita [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Salluh, Jorge [Auteur]
Universidade Federal do Estado do Rio de Janeiro [UNIRIO]
D'Or Institute for Research and Education [Rio de Janeiro]
Singer, Mervyn [Auteur]
University College of London [London] [UCL]
Sweeney, Daniel A. [Auteur]
University of California [San Diego] [UC San Diego]
Torres, Antoni [Auteur]
Centro de Investigación Biomédica en Red Enfermedades Respiratorias [CIBERES]
Universitat de Barcelona [UB]
Waterer, Grant [Auteur]
Royal Perth Hospital
Kalil, Andre C. [Auteur]
University of Nebraska Medical Center
Journal title :
Intensive Care Medicine
Abbreviated title :
Intensive Care Med
Volume number :
49
Pages :
142-153
Publisher :
Springer Science and Business Media LLC
Publication date :
2023-01-02
ISSN :
0342-4642
English keyword(s) :
Sepsis
Intensive care unit
Biomarkers
Diagnosis
Antibiotic stewardship
Intensive care unit
Biomarkers
Diagnosis
Antibiotic stewardship
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In this context, biomarkers could be considered as indicators of either infection or dysregulated host response ...
Show more >Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In this context, biomarkers could be considered as indicators of either infection or dysregulated host response or response to treatment and/or aid clinicians to prognosticate patient risk. More than 250 biomarkers have been identified and evaluated over the last few decades, but no biomarker accurately differentiates between sepsis and sepsis-like syndrome. Published data support the use of biomarkers for pathogen identification, clinical diagnosis, and optimization of antibiotic treatment. In this narrative review, we highlight how clinicians could improve the use of pathogen-specific and of the most used host-response biomarkers, procalcitonin and C-reactive protein, to improve the clinical care of patients with sepsis. Biomarker kinetics are more useful than single values in predicting sepsis, when making the diagnosis and assessing the response to antibiotic therapy. Finally, integrated biomarker-guided algorithms may hold promise to improve both the diagnosis and prognosis of sepsis. Herein, we provide current data on the clinical utility of pathogen-specific and host-response biomarkers, offer guidance on how to optimize their use, and propose the needs for future research.Show less >
Show more >Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In this context, biomarkers could be considered as indicators of either infection or dysregulated host response or response to treatment and/or aid clinicians to prognosticate patient risk. More than 250 biomarkers have been identified and evaluated over the last few decades, but no biomarker accurately differentiates between sepsis and sepsis-like syndrome. Published data support the use of biomarkers for pathogen identification, clinical diagnosis, and optimization of antibiotic treatment. In this narrative review, we highlight how clinicians could improve the use of pathogen-specific and of the most used host-response biomarkers, procalcitonin and C-reactive protein, to improve the clinical care of patients with sepsis. Biomarker kinetics are more useful than single values in predicting sepsis, when making the diagnosis and assessing the response to antibiotic therapy. Finally, integrated biomarker-guided algorithms may hold promise to improve both the diagnosis and prognosis of sepsis. Herein, we provide current data on the clinical utility of pathogen-specific and host-response biomarkers, offer guidance on how to optimize their use, and propose the needs for future research.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CNRS
CNRS
Research team(s) :
Glycobiology in fungal Pathogenesis and Clinical Applications
Submission date :
2024-03-01T13:42:45Z
2024-03-05T10:35:26Z
2024-03-05T10:35:26Z
Files
- P23.61 s00134-022-06956-y.pdf
- Version éditeur
- Restricted access
- Access the document